MaxCyte (MXCT) has released an update.
MaxCyte, Inc., a prominent player in cell-engineering technologies, has announced the grant of 325,608 stock options and 170,936 restricted stock units (RSUs) to its non-executive directors. These equity incentives, which will fully vest after a year, align with the company’s Equity Grant Policy and have an exercise period of ten years. With its ExPERT platform and 20 years of experience, MaxCyte continues to support the development of advanced cell-based therapies.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
